Top

Published in:

Open Access 01-12-2014 | Review

The impact of human hyperekplexia mutations on glycine receptor structure and function

Authors: Anna Bode, Joseph W Lynch

Published in: Molecular Brain | Issue 1/2014

Abstract

Hyperekplexia is a rare neurological disorder characterized by neonatal hypertonia, exaggerated startle responses to unexpected stimuli and a variable incidence of apnoea, intellectual disability and delays in speech acquisition. The majority of motor defects are successfully treated by clonazepam. Hyperekplexia is caused by hereditary mutations that disrupt the functioning of inhibitory glycinergic synapses in neuromotor pathways of the spinal cord and brainstem. The human glycine receptor α1 and β subunits, which predominate at these synapses, are the major targets of mutations. International genetic screening programs, that together have analysed several hundred probands, have recently generated a clear picture of genotype-phenotype correlations and the prevalence of different categories of hyperekplexia mutations. Focusing largely on this new information, this review seeks to summarise the effects of mutations on glycine receptor structure and function and how these functional alterations lead to hyperekplexia.

Available only for authorised users

Kirstein L, Silfverskiold BP: A family with emotionally precipitated drop seizures. Acta Psychiatr Neurol Scand. 1958, 33: 471-476. 10.1111/j.1600-0447.1958.tb03533.x.PubMed

Suhren O, Bruyn GW, Tuynman JA: Hyperexplexia - a hereditary startle syndrome. J Neurol Sci. 1966, 3: 577-605. 10.1016/0022-510X(66)90047-5.

Bakker MJ, van Dijk JG, van den Maagdenberg AM, Tijssen MA: Startle syndromes. Lancet Neurol. 2006, 5: 513-524. 10.1016/S1474-4422(06)70470-7.PubMed

Thomas RH, Chung SK, Wood SE, Cushion TD, Drew CJ, Hammond CL, Vanbellinghen JF, Mullins JG, Rees MI: Genotype-phenotype correlations in hyperekplexia: apnoeas, learning difficulties and speech delay. Brain. 2013, 136: 3085-3095. 10.1093/brain/awt207.PubMed

Thomas RH, Harvey RJ, Rees MI: Hyperekplexia: stiffness, startle and syncope. J Pediatr Neurol. 2010, 8: 11-14.

Zhou L, Chillag KL, Nigro MA: Hyperekplexia: a treatable neurogenetic disease. Brain Dev. 2002, 24: 669-674. 10.1016/S0387-7604(02)00095-5.PubMed

Shiang R, Ryan SG, Zhu YZ, Hahn AF, O’Connell P, Wasmuth JJ: Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. Nat Genet. 1993, 5: 351-358. 10.1038/ng1293-351.PubMed

Bode A, Wood SE, Mullins JG, Keramidas A, Cushion TD, Thomas RH, Pickrell WO, Drew CJ, Masri A, Jones EA, Vassallo G, Born AP, Alehan F, Aharoni S, Bannasch G, Bartsch M, Kara B, Krause A, Karam EG, Matta S, Jain V, Mandel H, Freilinger M, Graham GE, Hobson E, Chatfield S, Vincent-Delorme C, Rahme JE, Afawi Z, Berkovic SF, Howell OW, Vanbellinghen JF, Rees MI, Chung SK, Lynch JW: New hyperekplexia mutations provide insight into glycine receptor assembly, trafficking, and activation mechanisms. J Biol Chem. 2013, 288: 33745-33759. 10.1074/jbc.M113.509240.PubMedPubMedCentral

Chung SK, Vanbellinghen JF, Mullins JG, Robinson A, Hantke J, Hammond CL, Gilbert DF, Freilinger M, Ryan M, Kruer MC, Masri A, Gurses C, Ferrie C, Harvey K, Shiang R, Christodoulou J, Andermann F, Andermann E, Thomas RH, Harvey RJ, Lynch JW, Rees MI: Pathophysiological mechanisms of dominant and recessive GLRA1 mutations in hyperekplexia. J Neurosci. 2010, 30: 9612-9620. 10.1523/JNEUROSCI.1763-10.2010.PubMed

10.

Al-Owain M, Colak D, Al-Bakheet A, Al-Hashmi N, Shuaib T, Al-Hemidan A, Aldhalaan H, Rahbeeni Z, Al-Sayed M, Al-Younes B, Ozand PT, Kaya N: Novel mutation in GLRB in a large family with hereditary hyperekplexia. Clin Genet. 2012, 81: 479-484. 10.1111/j.1399-0004.2011.01661.x.PubMed

11.

Chung SK, Bode A, Cushion TD, Thomas RH, Hunt C, Wood SE, Pickrell WO, Drew CJ, Yamashita S, Shiang R, Leiz S, Longardt AC, Raile V, Weschke B, Puri RD, Verma IC, Harvey RJ, Ratnasinghe DD, Parker M, Rittey C, Masri A, Lingappa L, Howell OW, Vanbellinghen JF, Mullins JG, Lynch JW, Rees MI: GLRB is the third major gene of effect in hyperekplexia. Hum Mol Genet. 2013, 22: 927-940. 10.1093/hmg/dds498.PubMed

12.

James VM, Bode A, Chung SK, Gill JL, Nielsen M, Cowan FM, Vujic M, Thomas RH, Rees MI, Harvey K, Keramidas A, Topf M, Ginjaar I, Lynch JW, Harvey RJ: Novel missense mutations in the glycine receptor beta subunit gene (GLRB) in startle disease. Neurobiol Dis. 2013, 52: 137-149.PubMedPubMedCentral

13.

Lee CG, Kwon MJ, Yu HJ, Nam SH, Lee J, Ki CS, Lee M: Clinical features and genetic analysis of children with hyperekplexia in Korea. J Child Neurol. 2013, 28: 90-94. 10.1177/0883073812441058.PubMed

14.

Mine J, Taketani T, Otsubo S, Kishi K, Yamaguchi S: A 14-year-old girl with hyperekplexia having GLRB mutations. Brain Dev. 2013, 35: 660-663. 10.1016/j.braindev.2012.10.013.PubMed

15.

Rees MI, Lewis TM, Kwok JB, Mortier GR, Govaert P, Snell RG, Schofield PR, Owen MJ: Hyperekplexia associated with compound heterozygote mutations in the beta-subunit of the human inhibitory glycine receptor (GLRB). Hum Mol Genet. 2002, 11: 853-860. 10.1093/hmg/11.7.853.PubMed

16.

Carta E, Chung SK, James VM, Robinson A, Gill JL, Remy N, Vanbellinghen JF, Drew CJ, Cagdas S, Cameron D, Cowan FM, Del Toro M, Graham GE, Manzur AY, Masri A, Rivera S, Scalais E, Shiang R, Sinclair K, Stuart CA, Tijssen MA, Wise G, Zuberi SM, Harvey K, Pearce BR, Topf M, Thomas RH, Supplisson S, Rees MI, Harvey RJ: Mutations in the GlyT2 gene (SLC6A5) are a second major cause of startle disease. J Biol Chem. 2012, 287: 28975-28985. 10.1074/jbc.M112.372094.PubMedPubMedCentral

17.

Eulenburg V, Becker K, Gomeza J, Schmitt B, Becker CM, Betz H: Mutations within the human GLYT2 (SLC6A5) gene associated with hyperekplexia. Biochem Biophys Res Commun. 2006, 348: 400-405. 10.1016/j.bbrc.2006.07.080.PubMed

18.

Gimenez C, Perez-Siles G, Martinez-Villarreal J, Arribas-Gonzalez E, Jimenez E, Nunez E, de Juan-Sanz J, Fernandez-Sanchez E, Garcia-Tardon N, Ibanez I, Romanelli V, Nevado J, James VM, Topf M, Chung SK, Thomas RH, Desviat LR, Aragon C, Zafra F, Rees MI, Lapunzina P, Harvey RJ, Lopez-Corcuera B: A novel dominant hyperekplexia mutation Y705C alters trafficking and biochemical properties of the presynaptic glycine transporter GlyT2. J Biol Chem. 2012, 287: 28986-29002. 10.1074/jbc.M111.319244.PubMedPubMedCentral

19.

Rees MI, Harvey K, Pearce BR, Chung SK, Duguid IC, Thomas P, Beatty S, Graham GE, Armstrong L, Shiang R, Abbott KJ, Zuberi SM, Stephenson JB, Owen MJ, Tijssen MA, van den Maagdenberg AM, Smart TG, Supplisson S, Harvey RJ: Mutations in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of human startle disease. Nat Genet. 2006, 38: 801-806. 10.1038/ng1814.PubMedPubMedCentral

20.

Rees MI, Harvey K, Ward H, White JH, Evans L, Duguid IC, Hsu CC, Coleman SL, Miller J, Baer K, Waldvogel HJ, Gibbon F, Smart TG, Owen MJ, Harvey RJ, Snell RG: Isoform heterogeneity of the human gephyrin gene (GPHN), binding domains to the glycine receptor, and mutation analysis in hyperekplexia. J Biol Chem. 2003, 278: 24688-24696. 10.1074/jbc.M301070200.PubMed

21.

Harvey K, Duguid IC, Alldred MJ, Beatty SE, Ward H, Keep NH, Lingenfelter SE, Pearce BR, Lundgren J, Owen MJ, Smart TG, Luscher B, Rees MI, Harvey RJ: The GDP-GTP exchange factor collybistin: an essential determinant of neuronal gephyrin clustering. J Neurosci. 2004, 24: 5816-5826. 10.1523/JNEUROSCI.1184-04.2004.PubMed

22.

Chalphin AV, Saha MS: The specification of glycinergic neurons and the role of glycinergic transmission in development. Front Mol Neurosci. 2010, 3: 11-PubMedPubMedCentral

23.

Legendre P: The glycinergic inhibitory synapse. Cell Mol Life Sci. 2001, 58: 760-793. 10.1007/PL00000899.PubMed

24.

Lynch JW: Native glycine receptor subtypes and their physiological roles. Neuropharmacology. 2009, 56: 303-309. 10.1016/j.neuropharm.2008.07.034.PubMed

25.

Bode A, Lynch JW: Analysis of hyperekplexia mutations identifies transmembrane domain rearrangements that mediate glycine receptor activation. J Biol Chem. 2013, 288: 33760-33771. 10.1074/jbc.M113.513804.PubMedPubMedCentral

26.

Davies JS, Chung SK, Thomas RH, Robinson A, Hammond CL, Mullins JG, Carta E, Pearce BR, Harvey K, Harvey RJ, Rees MI: The glycinergic system in human startle disease: a genetic screening approach. Front Mol Neurosci. 2010, 3: 8-PubMedPubMedCentral

27.

Bocquet N, Nury H, Baaden M, Le Poupon C, Changeux JP, Delarue M, Corringer PJ: X-ray structure of a pentameric ligand-gated ion channel in an apparently open conformation. Nature. 2009, 457: 111-114. 10.1038/nature07462.PubMed

28.

Hilf RJ, Dutzler R: X-ray structure of a prokaryotic pentameric ligand-gated ion channel. Nature. 2008, 452: 375-379. 10.1038/nature06717.PubMed

29.

Hilf RJ, Dutzler R: Structure of a potentially open state of a proton-activated pentameric ligand-gated ion channel. Nature. 2009, 457: 115-118. 10.1038/nature07461.PubMed

30.

Unwin N: Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J Mol Biol. 2005, 346: 967-989. 10.1016/j.jmb.2004.12.031.PubMed

31.

Hibbs RE, Gouaux E: Principles of activation and permeation in an anion-selective Cys-loop receptor. Nature. 2011, 474: 54-60. 10.1038/nature10139.PubMedPubMedCentral

32.

Beato M, Groot-Kormelink PJ, Colquhoun D, Sivilotti LG: Openings of the rat recombinant alpha 1 homomeric glycine receptor as a function of the number of agonist molecules bound. J Gen Physiol. 2002, 119: 443-466. 10.1085/jgp.20028530.PubMedPubMedCentral

33.

Calimet N, Simoes M, Changeux JP, Karplus M, Taly A, Cecchini M: A gating mechanism of pentameric ligand-gated ion channels. Proc Natl Acad Sci USA. 2013, 110: E3987-E3996. 10.1073/pnas.1313785110.PubMedPubMedCentral

34.

Corringer PJ, Baaden M, Bocquet N, Delarue M, Dufresne V, Nury H, Prevost M, Van Renterghem C: Atomic structure and dynamics of pentameric ligand-gated ion channels: new insight from bacterial homologues. J Physiol. 2010, 588: 565-572. 10.1113/jphysiol.2009.183160.PubMedPubMedCentral

35.

Miller PS, Smart TG: Binding, activation and modulation of Cys-loop receptors. Trends Pharmacol Sci. 2010, 31: 161-174. 10.1016/j.tips.2009.12.005.PubMed

36.

Simon J, Wakimoto H, Fujita N, Lalande M, Barnard EA: Analysis of the set of GABA (A) receptor genes in the human genome. J Biol Chem. 2004, 279: 41422-41435. 10.1074/jbc.M401354200.PubMed

37.

Grudzinska J, Schemm R, Haeger S, Nicke A, Schmalzing G, Betz H, Laube B: The beta subunit determines the ligand binding properties of synaptic glycine receptors. Neuron. 2005, 45: 727-739. 10.1016/j.neuron.2005.01.028.PubMed

38.

Yang Z, Taran E, Webb TI, Lynch JW: Stoichiometry and subunit arrangement of alpha1beta glycine receptors as determined by atomic force microscopy. Biochemistry. 2012, 51: 5229-5231. 10.1021/bi300063m.PubMed

39.

Durisic N, Godin AG, Wever CM, Heyes CD, Lakadamyali M, Dent JA: Stoichiometry of the human glycine receptor revealed by direct subunit counting. J Neurosci. 2012, 32: 12915-12920. 10.1523/JNEUROSCI.2050-12.2012.PubMedPubMedCentral

40.

Meyer G, Kirsch J, Betz H, Langosch D: Identification of a gephyrin binding motif on the glycine receptor beta subunit. Neuron. 1995, 15: 563-572. 10.1016/0896-6273(95)90145-0.PubMed

41.

Watanabe E, Akagi H: Distribution patterns of mRNAs encoding glycine receptor channels in the developing rat spinal cord. Neurosci Res. 1995, 23: 377-382. 10.1016/0168-0102(95)00972-V.PubMed

42.

Harvey RJ, Depner UB, Wassle H, Ahmadi S, Heindl C, Reinold H, Smart TG, Harvey K, Schutz B, Abo-Salem OM, Zimmer A, Poisbeau P, Welzl H, Wolfer DP, Betz H, Zeilhofer HU, Muller U: GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science. 2004, 304: 884-887. 10.1126/science.1094925.PubMed

43.

Avila A, Vidal PM, Dear TN, Harvey RJ, Rigo JM, Nguyen L: Glycine receptor alpha2 subunit activation promotes cortical interneuron migration. Cell Rep. 2013, 4: 738-750. 10.1016/j.celrep.2013.07.016.PubMedPubMedCentral

44.

Jonsson S, Morud J, Pickering C, Adermark L, Ericson M, Soderpalm B: Changes in glycine receptor subunit expression in forebrain regions of the Wistar rat over development. Brain Res. 2012, 1446: 12-21.PubMed

45.

Thio LL, Shanmugam A, Isenberg K, Yamada K: Benzodiazepines block alpha2-containing inhibitory glycine receptors in embryonic mouse hippocampal neurons. J Neurophysiol. 2003, 90: 89-99. 10.1152/jn.00612.2002.PubMed

46.

Young-Pearse TL, Ivic L, Kriegstein AR, Cepko CL: Characterization of mice with targeted deletion of glycine receptor alpha 2. Mol Cell Biol. 2006, 26: 5728-5734. 10.1128/MCB.00237-06.PubMedPubMedCentral

47.

Rees MI, Andrew M, Jawad S, Owen MJ: Evidence for recessive as well as dominant forms of startle disease (hyperekplexia) caused by mutations in the alpha 1 subunit of the inhibitory glycine receptor. Hum Mol Genet. 1994, 3: 2175-2179. 10.1093/hmg/3.12.2175.PubMed

48.

Vergouwe MN, Tijssen MA, Peters AC, Wielaard R, Frants RR: Hyperekplexia phenotype due to compound heterozygosity for GLRA1 gene mutations. Ann Neurol. 1999, 46: 634-638. 10.1002/1531-8249(199910)46:4<634::AID-ANA12>3.0.CO;2-9.PubMed

49.

del Giudice EM, Coppola G, Bellini G, Cirillo G, Scuccimarra G, Pascotto A: A mutation (V260M) in the middle of the M2 pore-lining domain of the glycine receptor causes hereditary hyperekplexia. Eur J Hum Genet. 2001, 9: 873-876. 10.1038/sj.ejhg.5200729.PubMed

50.

Brune W, Weber RG, Saul B, von Knebel Doeberitz M, Grond-Ginsbach C, Kellerman K, Meinck HM, Becker CM: A GLRA1 null mutation in recessive hyperekplexia challenges the functional role of glycine receptors. Am J Hum Genet. 1996, 58: 989-997.PubMedPubMedCentral

51.

Tsai CH, Chang FC, Su YC, Tsai FJ, Lu MK, Lee CC, Kuo CC, Yang YW, Lu CS: Two novel mutations of the glycine receptor gene in a Taiwanese hyperekplexia family. Neurology. 2004, 63: 893-896. 10.1212/01.WNL.0000138566.65519.67.PubMed

52.

Rees MI, Lewis TM, Vafa B, Ferrie C, Corry P, Muntoni F, Jungbluth H, Stephenson JB, Kerr M, Snell RG, Schofield PR, Owen MJ: Compound heterozygosity and nonsense mutations in the alpha (1)-subunit of the inhibitory glycine receptor in hyperekplexia. Hum Genet. 2001, 109: 267-270. 10.1007/s004390100569.PubMed

53.

Coto E, Armenta D, Espinosa R, Argente J, Castro MG, Alvarez V: Recessive hyperekplexia due to a new mutation (R100H) in the GLRA1 gene. Mov Disord. 2005, 20: 1626-1629. 10.1002/mds.20637.PubMed

54.

Zoons E, Ginjaar IB, Bouma PA, Carpay JA, Tijssen MA: A new hyperekplexia family with a recessive frameshift mutation in the GLRA1 gene. Mov Disord. 2012, 27: 795-796. 10.1002/mds.24917.PubMed

55.

Chan KK, Cherk SW, Lee HH, Poon WT, Chan AY: Hyperekplexia: a Chinese adolescent with 2 novel mutations of the GLRA1 gene. J Child Neurol. 2012, 29: 111-113.PubMed

56.

Al-Futaisi AM, Al-Kindi MN, Al-Mawali AM, Koul RL, Al-Adawi S, Al-Yahyaee SA: Novel mutation of GLRA1 in Omani families with hyperekplexia and mild mental retardation. Pediatr Neurol. 2012, 46: 89-93. 10.1016/j.pediatrneurol.2011.11.008.PubMed

57.

Forsyth RJ, Gika AD, Ginjaar I, Tijssen MA: A novel GLRA1 mutation in a recessive hyperekplexia pedigree. Mov Disord. 2007, 22: 1643-1645. 10.1002/mds.21574.PubMed

58.

Humeny A, Bonk T, Becker K, Jafari-Boroujerdi M, Stephani U, Reuter K, Becker CM: A novel recessive hyperekplexia allele GLRA1 (S231R): genotyping by MALDI-TOF mass spectrometry and functional characterisation as a determinant of cellular glycine receptor trafficking. Eur J Hum Genet. 2002, 10: 188-196. 10.1038/sj.ejhg.5200779.PubMed

59.

Gilbert SL, Ozdag F, Ulas UH, Dobyns WB, Lahn BT: Hereditary hyperekplexia caused by novel mutations of GLRA1 in Turkish families. Mol Diagn. 2004, 8: 151-155.PubMed

60.

Saul B, Kuner T, Sobetzko D, Brune W, Hanefeld F, Meinck HM, Becker CM: Novel GLRA1 missense mutation (P250T) in dominant hyperekplexia defines an intracellular determinant of glycine receptor channel gating. J Neurosci. 1999, 19: 869-877.PubMed

61.

Milani N, Dalpra L, del Prete A, Zanini R, Larizza L: A novel mutation (Gln266 - > His) in the alpha 1 subunit of the inhibitory glycine-receptor gene (GLRA1) in hereditary hyperekplexia. Am J Hum Genet. 1996, 58: 420-422.PubMedPubMedCentral

62.

Becker K, Breitinger HG, Humeny A, Meinck HM, Dietz B, Aksu F, Becker CM: The novel hyperekplexia allele GLRA1(S267N) affects the ethanol site of the glycine receptor. Eur J Hum Genet. 2008, 16: 223-228. 10.1038/sj.ejhg.5201958.PubMed

63.

Lapunzina P, Sanchez JM, Cabrera M, Moreno A, Delicado A, de Torres ML, Mori AM, Quero J, Lopez Pajares I: Hyperekplexia (startle disease): a novel mutation (S270T) in the M2 domain of the GLRA1 gene and a molecular review of the disorder. Mol Diagn. 2003, 7: 125-128.PubMed

64.

Gregory ML, Guzauskas GF, Edgar TS, Clarkson KB, Srivastava AK, Holden KR: A novel GLRA1 mutation associated with an atypical hyperekplexia phenotype. J Child Neurol. 2008, 23: 1433-1438. 10.1177/0883073808320754.PubMed

65.

Elmslie FV, Hutchings SM, Spencer V, Curtis A, Covanis T, Gardiner RM, Rees M: Analysis of GLRA1 in hereditary and sporadic hyperekplexia: a novel mutation in a family cosegregating for hyperekplexia and spastic paraparesis. J Med Genet. 1996, 33: 435-436. 10.1136/jmg.33.5.435.PubMedPubMedCentral

66.

Kang HC, Jeong You S, Jae Chey M, Sam Baik J, Kim JW, Ki CS: Identification of a de novo Lys304Gln mutation in the glycine receptor alpha-1 subunit gene in a Korean infant with hyperekplexia. Mov Disord. 2008, 23: 610-613. 10.1002/mds.21909.PubMed

67.

Shiang R, Ryan SG, Zhu YZ, Fielder TJ, Allen RJ, Fryer A, Yamashita S, O’Connell P, Wasmuth JJ: Mutational analysis of familial and sporadic hyperekplexia. Ann Neurol. 1995, 38: 85-91. 10.1002/ana.410380115.PubMed

68.

Poon WT, Au KM, Chan YW, Chan KY, Chow CB, Tong SF, Lam CW: Novel missense mutation (Y279S) in the GLRA1 gene causing hyperekplexia. Clin Chim Acta. 2006, 364: 361-362. 10.1016/j.cca.2005.09.018.PubMed

69.

Bellini G, Miceli F, Mangano S, Miraglia Del Giudice E, Coppola G, Barbagallo A, Taglialatela M, Pascotto A: Hyperekplexia caused by dominant-negative suppression of glyra1 function. Neurology. 2007, 68: 1947-1949. 10.1212/01.wnl.0000263193.75291.85.PubMed

70.

Jungbluth H, Rees MI, Manzur AY, Mercuri E, Sewry CA, Gobbi P, Muntoni F: An unusual case of hyperekplexia. Eur J Paediatr Neurol. 2000, 4: 77-80. 10.1053/ejpn.1999.0267.PubMed

71.

Engel AG, Shen XM, Selcen D, Sine SM: What have we learned from the congenital myasthenic syndromes. J Mol Neurosci. 2010, 40: 143-153. 10.1007/s12031-009-9229-0.PubMedPubMedCentral

72.

Tijssen MA, Shiang R, van Deutekom J, Boerman RH, Wasmuth JJ, Sandkuijl LA, Frants RR, Padberg GW: Molecular genetic reevaluation of the Dutch hyperekplexia family. Arch Neurol. 1995, 52: 578-582. 10.1001/archneur.1995.00540300052012.PubMed

73.

Langosch D, Laube B, Rundstrom N, Schmieden V, Bormann J, Betz H: Decreased agonist affinity and chloride conductance of mutant glycine receptors associated with human hereditary hyperekplexia. EMBO J. 1994, 13: 4223-4228.PubMedPubMedCentral

74.

Lynch JW, Rajendra S, Pierce KD, Handford CA, Barry PH, Schofield PR: Identification of intracellular and extracellular domains mediating signal transduction in the inhibitory glycine receptor chloride channel. EMBO J. 1997, 16: 110-120. 10.1093/emboj/16.1.110.PubMedPubMedCentral

75.

Maksay G, Biro T, Laube B: Hyperekplexia mutation of glycine receptors: decreased gating efficacy with altered binding thermodynamics. Biochem Pharmacol. 2002, 64: 285-288. 10.1016/S0006-2952(02)01111-5.PubMed

76.

Rajendra S, Lynch JW, Pierce KD, French CR, Barry PH, Schofield PR: Startle disease mutations reduce the agonist sensitivity of the human inhibitory glycine receptor. J Biol Chem. 1994, 269: 18739-18742.PubMed

77.

Rajendra S, Lynch JW, Pierce KD, French CR, Barry PH, Schofield PR: Mutation of an arginine residue in the human glycine receptor transforms beta-alanine and taurine from agonists into competitive antagonists. Neuron. 1995, 14: 169-175. 10.1016/0896-6273(95)90251-1.PubMed

78.

Keramidas A, Moorhouse AJ, Schofield PR, Barry PH: Ligand-gated ion channels: mechanisms underlying ion selectivity. Prog Biophys Mol Biol. 2004, 86: 161-204. 10.1016/j.pbiomolbio.2003.09.002.PubMed

79.

Colquhoun D: Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol. 1998, 125: 924-947.PubMed

80.

Lape R, Plested AJ, Moroni M, Colquhoun D, Sivilotti LG: The alpha1K276E startle disease mutation reveals multiple intermediate states in the gating of glycine receptors. J Neurosci. 2012, 32: 1336-1352. 10.1523/JNEUROSCI.4346-11.2012.PubMed

81.

Lewis TM, Sivilotti LG, Colquhoun D, Gardiner RM, Schoepfer R, Rees M: Properties of human glycine receptors containing the hyperekplexia mutation alpha1(K276E), expressed in Xenopus oocytes. J Physiol. 1998, 507 (Pt 1): 25-40.PubMedPubMedCentral

82.

Schaefer N, Langlhofer G, Kluck CJ, Villmann C: Glycine receptor mouse mutants: model systems for human hyperekplexia. Br J Pharmacol. 2013, 170: 933-952. 10.1111/bph.12335.PubMedPubMedCentral

83.

Shan Q, Han L, Lynch JW: Function of hyperekplexia-causing alpha1R271Q/L glycine receptors is restored by shifting the affected residue out of the allosteric signalling pathway. Br J Pharmacol. 2012, 165: 2113-2123. 10.1111/j.1476-5381.2011.01701.x.PubMedPubMedCentral

84.

Nussinov R: Allosteric modulators can restore function in an amino acid neurotransmitter receptor by slightly altering intra-molecular communication pathways. Br J Pharmacol. 2012, 165: 2110-2112. 10.1111/j.1476-5381.2011.01793.x.PubMedPubMedCentral

85.

Maksay G, Biro T, Laube B, Nemes P: Hyperekplexia mutation R271L of alpha1 glycine receptors potentiates allosteric interactions of nortropeines, propofol and glycine with [3H] strychnine binding. Neurochem Int. 2008, 52: 235-240. 10.1016/j.neuint.2007.06.009.PubMed

86.

O’Shea SM, Becker L, Weiher H, Betz H, Laube B: Propofol restores the function of “hyperekplexic” mutant glycine receptors in Xenopus oocytes and mice. J Neurosci. 2004, 24: 2322-2327. 10.1523/JNEUROSCI.4675-03.2004.PubMed

87.

Nury H, Van Renterghem C, Weng Y, Tran A, Baaden M, Dufresne V, Changeux JP, Sonner JM, Delarue M, Corringer PJ: X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel. Nature. 2011, 469: 428-431. 10.1038/nature09647.PubMed

88.

Moorhouse AJ, Jacques P, Barry PH, Schofield PR: The startle disease mutation Q266H, in the second transmembrane domain of the human glycine receptor, impairs channel gating. Mol Pharmacol. 1999, 55: 386-395.PubMed

89.

Castaldo P, Stefanoni P, Miceli F, Coppola G, Del Giudice EM, Bellini G, Pascotto A, Trudell JR, Harrison NL, Annunziato L, Taglialatela M: A novel hyperekplexia-causing mutation in the pre-transmembrane segment 1 of the human glycine receptor alpha1 subunit reduces membrane expression and impairs gating by agonists. J Biol Chem. 2004, 279: 25598-25604. 10.1074/jbc.M311021200.PubMed

90.

Pless SA, Leung AW, Galpin JD, Ahern CA: Contributions of conserved residues at the gating interface of glycine receptors. J Biol Chem. 2011, 286: 35129-35136. 10.1074/jbc.M111.269027.PubMedPubMedCentral

91.

Breitinger HG, Villmann C, Becker K, Becker CM: Opposing effects of molecular volume and charge at the hyperekplexia site alpha 1(P250) govern glycine receptor activation and desensitization. J Biol Chem. 2001, 276: 29657-29663. 10.1074/jbc.M100446200.PubMed

92.

Breitinger HG, Lanig H, Vohwinkel C, Grewer C, Breitinger U, Clark T, Becker CM: Molecular dynamics simulation links conformation of a pore-flanking region to hyperekplexia-related dysfunction of the inhibitory glycine receptor. Chem Biol. 2004, 11: 1339-1350. 10.1016/j.chembiol.2004.07.008.PubMed

93.

Wang Q, Lynch JW: Activation and desensitization induce distinct conformational changes at the extracellular-transmembrane domain interface of the glycine receptor. J Biol Chem. 2011, 286: 38814-38824. 10.1074/jbc.M111.273631.PubMedPubMedCentral

94.

Villmann C, Oertel J, Melzer N, Becker CM: Recessive hyperekplexia mutations of the glycine receptor alpha1 subunit affect cell surface integration and stability. J Neurochem. 2009, 111: 837-847. 10.1111/j.1471-4159.2009.06372.x.PubMed

95.

Villmann C, Oertel J, Ma-Hogemeier ZL, Hollmann M, Sprengel R, Becker K, Breitinger HG, Becker CM: Functional complementation of Glra1(spd-ot), a glycine receptor subunit mutant, by independently expressed C-terminal domains. J Neurosci. 2009, 29: 2440-2452. 10.1523/JNEUROSCI.4400-08.2009.PubMed

96.

Laube B, Kuhse J, Rundstrom N, Kirsch J, Schmieden V, Betz H: Modulation by zinc ions of native rat and recombinant human inhibitory glycine receptors. J Physiol. 1995, 483 (Pt 3): 613-619.PubMedPubMedCentral

97.

Hirzel K, Muller U, Latal AT, Hulsmann S, Grudzinska J, Seeliger MW, Betz H, Laube B: Hyperekplexia phenotype of glycine receptor alpha1 subunit mutant mice identifies Zn (2+) as an essential endogenous modulator of glycinergic neurotransmission. Neuron. 2006, 52: 679-690. 10.1016/j.neuron.2006.09.035.PubMed

98.

Zhou N, Wang CH, Zhang S, Wu DC: The GLRA1 missense mutation W170S associates lack of Zn2+ potentiation with human hyperekplexia. J Neurosci. 2013, 33: 17675-17681. 10.1523/JNEUROSCI.3240-13.2013.PubMedPubMedCentral

99.

Bianchi MT, Macdonald RL: Mutation of the 9′ leucine in the GABA (A) receptor gamma2L subunit produces an apparent decrease in desensitization by stabilizing open states without altering desensitized states. Neuropharmacology. 2001, 41: 737-744. 10.1016/S0028-3908(01)00132-0.PubMed

100.

Chang Y, Weiss DS: Substitutions of the highly conserved M2 leucine create spontaneously opening rho1 gamma-aminobutyric acid receptors. Mol Pharmacol. 1998, 53: 511-523.PubMed

101.

Chang Y, Weiss DS: Allosteric activation mechanism of the alpha 1 beta 2 gamma 2 gamma-aminobutyric acid type A receptor revealed by mutation of the conserved M2 leucine. Biophys J. 1999, 77: 2542-2551. 10.1016/S0006-3495(99)77089-X.PubMedPubMedCentral

102.

Tierney ML, Birnir B, Pillai NP, Clements JD, Howitt SM, Cox GB, Gage PW: Effects of mutating leucine to threonine in the M2 segment of alpha1 and beta1 subunits of GABAA alpha1beta1 receptors. J Membr Biol. 1996, 154: 11-21. 10.1007/s002329900128.PubMed

103.

Ganser LR, Yan Q, James VM, Kozol R, Topf M, Harvey RJ, Dallman JE: Distinct phenotypes in zebrafish models of human startle disease. Neurobiol Dis. 2013, 60: 139-151.PubMedPubMedCentral

104.

Lynch JW: Molecular structure and function of the glycine receptor chloride channel. Physiol Rev. 2004, 84: 1051-1095. 10.1152/physrev.00042.2003.PubMed

Title: The impact of human hyperekplexia mutations on glycine receptor structure and function
Authors: Anna Bode
Joseph W Lynch
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Molecular Brain / Issue 1/2014
Electronic ISSN: 1756-6606
DOI: https://doi.org/10.1186/1756-6606-7-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The impact of human hyperekplexia mutations on glycine receptor structure and function

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa

The planar cell polarity protein Vangl2 bidirectionally regulates dendritic branching in cultured hippocampal neurons

Absence of BRINP1 in mice causes increase of hippocampal neurogenesis and behavioral alterations relevant to human psychiatric disorders

Inorganic polyphosphate regulates neuronal excitability through modulation of voltage-gated channels

Neuronal representation of working memory in the medial prefrontal cortex of rats

Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease